Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mechanism of efficacy of trabectedin against myxoid liposarcoma entails detachment of the FUS-DDIT3 transcription factor from its DNA binding sites.
Craparotta I, Mannarino L, Zadro R, Ballabio S, Marchini S, Pavesi G, Russo M, Renne SL, Meroni M, Ponzo M, Bello E, Sanfilippo R, Casali PG, D'Incalci M, Frapolli R. Craparotta I, et al. Among authors: bello e. J Exp Clin Cancer Res. 2024 Nov 26;43(1):309. doi: 10.1186/s13046-024-03228-z. J Exp Clin Cancer Res. 2024. PMID: 39587691 Free PMC article.
Mode of action of trabectedin in myxoid liposarcomas.
Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, Gronchi A, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JM, D'Incalci M. Di Giandomenico S, et al. Among authors: bello e. Oncogene. 2014 Oct 30;33(44):5201-10. doi: 10.1038/onc.2013.462. Epub 2013 Nov 11. Oncogene. 2014. PMID: 24213580
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L, Beltrame L, Marchini S, Galmarini CM, Mantovani A, Frapolli R, Allavena P, D'Incalci M. Belgiovine C, et al. Among authors: bello e. Br J Cancer. 2017 Aug 22;117(5):628-638. doi: 10.1038/bjc.2017.205. Epub 2017 Jul 6. Br J Cancer. 2017. PMID: 28683469 Free PMC article.
Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
Frapolli R, Bello E, Ponzo M, Craparotta I, Mannarino L, Ballabio S, Marchini S, Carrassa L, Ubezio P, Porcu L, Brich S, Sanfilippo R, Casali PG, Gronchi A, Pilotti S, D'Incalci M. Frapolli R, et al. Among authors: bello e. Clin Cancer Res. 2019 Dec 15;25(24):7565-7575. doi: 10.1158/1078-0432.CCR-19-0976. Epub 2019 Sep 3. Clin Cancer Res. 2019. PMID: 31481505 Free article.
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.
Romano M, Della Porta MG, Gallì A, Panini N, Licandro SA, Bello E, Craparotta I, Rosti V, Bonetti E, Tancredi R, Rossi M, Mannarino L, Marchini S, Porcu L, Galmarini CM, Zambelli A, Zecca M, Locatelli F, Cazzola M, Biondi A, Rambaldi A, Allavena P, Erba E, D'Incalci M. Romano M, et al. Among authors: bello e. Br J Cancer. 2017 Jan;116(3):335-343. doi: 10.1038/bjc.2016.424. Epub 2017 Jan 10. Br J Cancer. 2017. PMID: 28072764 Free PMC article.
Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin.
Capasso Palmiero U, Morosi L, Bello E, Ponzo M, Frapolli R, Matteo C, Ferrari M, Zucchetti M, Minoli L, De Maglie M, Romanelli P, Morbidelli M, D'Incalci M, Moscatelli D. Capasso Palmiero U, et al. Among authors: bello e. J Control Release. 2018 Apr 28;276:140-149. doi: 10.1016/j.jconrel.2018.03.005. Epub 2018 Mar 7. J Control Release. 2018. PMID: 29524443
171 results